We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Differential Gene Expression Aids Disseminated Tumor Cells Adapt to Diverse Microenvironments

By LabMedica International staff writers
Posted on 09 Nov 2015
A recent paper described how cancer cells that have broken away from a primary tumor are able to establish the conditions they need to survive in a distant site that possesses a quite different microenvironment.

Investigators at the University of Notre Dame (South Bend, IN, USA) and at the University of Texas MD Anderson Cancer Center (Houston, USA) reported in the October 19, 2015, online edition of the journal Nature that the ability of disseminated tumor cells to establish themselves in distant locations was dependent on expressing or silencing the tumor suppressor gene PTEN.

PTEN (phosphatase and tensin homolog) is one of the most commonly lost tumor suppressors in human cancer. More...
During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, prostate cancer, and reduced expression is found in many other tumor types such as lung and breast cancer. When the PTEN enzyme is functioning properly, it acts as part of a chemical pathway that signals cells to stop dividing and causes cells to undergo programmed cell death (apoptosis) when necessary. These functions prevent uncontrolled cell growth that can lead to the formation of tumors. There is also evidence that the protein made by the PTEN gene may play a role in both cell movement and adhesion of cells to surrounding tissues.

The investigators found that both human and mouse tumor cells with normal expression of PTEN lost expression of this gene after dissemination to the brain, but not to other organs. The PTEN level in PTEN-loss brain metastatic tumor cells was restored after leaving the brain microenvironment. This brain microenvironment-dependent, reversible PTEN messenger RNA and protein downregulation was epigenetically regulated by microRNAs from brain astrocytes.

Astrocyte-derived exosomes mediated an intercellular transfer of PTEN-targeting microRNAs to metastatic tumor cells, while astrocyte-specific depletion of PTEN-targeting microRNAs or blockade of astrocyte exosome secretion rescued the PTEN loss and suppressed brain metastasis in vivo. This adaptive PTEN loss in brain metastatic tumor cells led to an increased secretion of the chemokine CCL2, which recruited myeloid cells that reciprocally enhanced the outgrowth of brain metastatic tumor cells via enhanced proliferation and reduced apoptosis.

Contributing author Dr. Siyuan Zhang, professor of cancer research at Notre Dame University, said, "The microenvironment has tremendous impact on how the gene is expressed, what type of gene will be expressed. It is definitely not due to genetic mutation. The point of this paper is we should not overlook the huge influence of the tissue architecture, the tissue environment, the tissue composition. It is a dynamic process."

Related Links:

University of Notre Dame
University of Texas MD Anderson Cancer Center 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.